Company intelligence / Profile preview

Pierre Fabre Laboratories

Castres, Midi-Pyrénées, Francepierre-fabre.com ↗

Ownership: Private
Employees: ~11500
Development stage: Commercial

Overview

Pierre Fabre has multiple approved products and an active pipeline in oncology and rare diseases. Recent developments include a Phase I/II clinical trial for PFL-002/VERT-002, a c-MET targeting therapy for NSCLC, and UK regulatory approval for vibegron (Obgemsa) to treat overactive bladder syndrome in July 2024[5][6].

Therapeutic areas: UrologyDermatologyOtherOncologyRare DiseasesInfectious Diseases
Modalities: Small moleculesmonoclonal antibodies (mAbs)cell therapy
Industry: Biotech

Drug pipeline

58 assets

vinorelbine

Approved

57 more assets in the full pipeline.

Request access →

Partnerships

Puma BiotechnologyAtara BiotherapeuticsPfizerScorpion TherapeuticsVertical BioVernalis LtdIHU healthAge

Beyond the preview

Go deeper on Pierre Fabre Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pierre Fabre Laboratories.

Explore the full profile